<DOC>
	<DOCNO>NCT00506298</DOCNO>
	<brief_summary>This trial ass efficacy CRx-401 lower FPG level patient take metformin treat diabetes . In addition , initial trial evaluate insulin resistance ( HOMA-IR index ) , HgbA1c level , glycated protein , LDL , HDL , triglyceride , total cholesterol , well safety CRx-401 .</brief_summary>
	<brief_title>Study CRx-401 Glucose Levels Subjects With Type II Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Diflunisal</mesh_term>
	<mesh_term>Bezafibrate</mesh_term>
	<criteria>Must voluntarily give write informed consent Must 1875 year age Must Type 2 diabetes ≥ 6 month HgbA1C 7.0 % 9.5 % FPG &gt; 6.7 mmol/L ( 120 mg/dL ) BMI : Lower limit 27 kg/m2 upper Limit 45 kg/m2 Treatment stable dosage ≥ 8 week either Glucophage metformin ) ≥ 1000 ≤ 2500 mg/day OR Glucophage XR ≤ 2000 mg/day eGFR ≥ 70 mL/min History clinically significant atherosclerotic disorder include myocardial infarction ( within 6 month screen ) , angina , stroke , peripheral vascular disease congestive heart failure Known hypersensitivity idiosyncratic reaction relate fibrates NSAIDs include photoallergic phototoxic reaction fibrates Subjects acute asthmatic attack , urticaria , rhinitis precipitate aspirin NSAIDs History clinically significant ( determined investigator cardiac , hematologic , hepatobiliary , peptic ulcer , renal , immunologic , metabolic , urologic , pulmonary , endocrinologic , neurologic , dermatologic , psychiatric , and/or major disease Type 1 Diabetes Evidence Cushing 's syndrome , untreated hypothyroidism disorder may lead secondary weight gain , insulin resistance , Type 2 diabetes Proliferative diabetic retinopathy significant neuropathic symptom also limit activity daily live History malignancy ( except treat excised basal cell carcinoma ) Surgery within 90 day prior screen except minor dental cosmetic procedure History drug alcohol abuse ( define Investigator ) History opportunistic infection Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , septicemia ) within 3 month prior screen Fever symptomatic viral bacterial infection within 2 week prior screen Positive HCV antibody Positive HBsAg Known positive HIV antibody Pharmacologic treatment statin , unless dosage stable ≥ three month unlikely change course study . Treatment concomitant medication stable dose least 28 day prior screen . Currently take plan take trial : Sulphonylureas , Injected hypoglycemic ( exanatide insulin ) , Weight loss medication , Thiazolidenediones , Glucocorticoids ( inhaled glucocorticoid permit ) , Digoxin , Anticoagulants , Phenytoin , Loratadine , Erythromycin , MAOinhibitors , NSAIDs ( ASA ≤ 81 mg/d permit ) , COX2 Inhibitors , Cholestryramine fibrates , DPPIV inhibitor , Any herbal medication unless review study doctor Alanine aminotransferase ALT ) aspartate aminotransferase ( AST laboratory value exceed &gt; 2.0 x upper limit normal ( ULN ) White blood cell ( WBC ) count &lt; 4.0 x 109 /L &gt; 14.0 X 109 /L Hemoglobin &lt; 105 g/L female &lt; 110 g/L male ( &lt; 10.5 g/dL female &lt; 11.0 g/dL male ) Participation another clinical trial and/or treatment receive investigational agent within 30 day initial dose study medication Female subject pregnant lactating child bear potential use acceptable method contraception ( birth control pill , barrier abstinence ) Unwilling unable comply requirement protocol , include presence condition ( physical , mental , social ) likely affect subject 's return followup visit schedule Other unspecified reason , opinion Investigator sponsor make subject unsuitable enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>CRx-401</keyword>
	<keyword>Bezafibrate</keyword>
	<keyword>Diflunisal</keyword>
	<keyword>Metformin</keyword>
	<keyword>plasma glucose</keyword>
</DOC>